Naslov
Use of antihypertensive and cardiovascular agents during pregnancy

Autori
Leppee, Marcel ; Marić-Bajs, Maja ; Čulig, Josip

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
European Meeting on Hypertension and Cardiovascular Protection (ESH 2012) ; Abstract: Journal of Hypertension 2012 ; 30(e-Supplement A):e210 / - , 2012

Skup
European Meeting on Hypertension and Cardiovascular Protection (ESH 2012) ;

Mjesto i datum
London, Ujedinjeno Kraljevstvo, 26.04.2012. - 29.04.2012

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
antihypertensive; cardiovascular

Sažetak
Objective Prescribing drugs during pregnancy poses a challenge to the physician to balance optimal treatment of the maternal symptoms and disease against the possible harm to the fetus. The aim of the study was to assess the prevalence of using antyhypertensive and cardiovascular agents in pregnancy and the possible association of congenital malformations with the use of these drugs. Design and Method One arm of the study (one-month study) was performed at four maternity hospitals in Zagreb, Croatia. The other arm of the study (one-year study) was performed at University Department of Gynecology and Obstetrics, Genetic Counseling Unit, and Department of Pathology and Histology in Novi Sad, Serbia. Only pregnant women using drugs for cardiovascular disorders during pregnancy were included in the study. Final analysis included data on 134 (32+102) pregnant women. Results Data analysis showed the use of drugs for cardiovascular disorders during pregnancy in 134 (1.9%) of 6992 (6099+893) women. According to data collected in the Zagreb arm, the prevalence of cardiac disorders in pregnancy was 3.6% (n=32), whereas data from the Novi Sad arm indicated a prevalence of 1.7% (n=102), yielding a predominant use of -blockers in Zagreb (n=32 ; 3.6%) and of antihypertensive agents in Novi Sad (n=64 ; 1.0%). In Zagreb, malformations were detected in 26 (2.9%) fetuses and newborns in the general population and in 3 (9.4%) fetuses and newborns in utero exposed to cardiovascular agents. The prevalence of congenital malformations in fetuses at in utero exposure to FDA class D drugs was 3.1% (n=1). In Novi Sad, malformations were detected in 326 (5.35%) fetuses and newborns in the general population and in 5 (4.9%) fetuses and newborns in utero exposed to drugs for cardiovascular disorders. Conclusions The exact cause of these malformations cannot be positively identified because the fetus is generally not exposed to a single teratogenic factor but to a combination of such effects.

Izvorni jezik
Engleski

Znanstvena područja
Javno zdravstvo i zdravstvena zaštita

POVEZANOST RADA